No Data
Suzhou Basecare Medical Expects Up to 47% Rise in 2024 Revenue
Beikang Medical (2170.HK): Performance is steadily growing in 2024, sales expectations are met, and the advantages of the Global Industry Chain are beginning to show results.
In the era of low sentiment in the Medical Sector, Beikang Medical's announcement of exceeding sales expectations for 2024 is refreshing.
BASECARE-B (02170.HK): Revenue in 2024 is expected to increase by approximately 41.8%–46.6% year-on-year.
Gelonghui January 13丨BASECARE-B (02170.HK) announced that for the year ending December 31, 2024, the Group achieved revenue of approximately RMB 2.95–0.305 billion, a year-on-year increase of around 41.8%–46.6%. The increase in revenue was mainly due to the following reasons: (i) the Group's acquisition of Singapore BMX Holdco Pte. Ltd. enabled international sales of independently developed products in China through its Global sales network, driving the Group's Global sales revenue growth; (ii) in 2024, the Group successfully developed important client relationships.
Express News | Suzhou Basecare Medical Corp - Unaudited Operating Statistics Revenue for FY RMB295.0 Mln-RMB305.0 Mln
BASECARE-B (02170): Zhao has been nominated as a non-executive Director.
BASECARE-B (02170) announces that the Board of Directors has reviewed and approved the re-election of Jiang Junchao for...
Industry Partnership | Basecare Medical Group (2170.HK) and Jinghua Medical Group Sign Strategic Cooperation Agreement
No Data
